While mainstream industries continue to experience considerable losses in the midst of the ongoing pandemic, legal cannabis has demonstrated its impressive growth potential in this volatile market. U.S. stock futures were trading sharply lower on Wednesday as growing COVID-19 pandemic dashed hopes of a global economic recovery, despite huge gains in the tech sector during the previous session that propelled the Nasdaq composite to an all-time closing high. Jul 08, 2020 (Market Insight Reports) —
Selbyville, Delaware. The report Intravenous Immunoglobulin (IVIg) Market Analysis and forecast 2025 maintains… Stocks trended lower into the close Tuesday as the tech rally lost steam. Three experts break down what to watch now.
While mainstream industries continue to experience considerable losses in the midst of the ongoing pandemic, legal cannabis has demonstrated its impressive growth potential in this volatile market. As consumer and political demand for cannabis reaches record highs, one multi-state operator (MSO) has strategically positioned itself to generate explosive returns and dwarf the competition in the coming months.
This week, analysts at Clarus Securities increased their second quarter and full year earnings projections for North American operator TerrAscend after the company’s strong performance in Pennsylvania this year. Clarus now projects that TerrAscend’s second quarter earnings will reach C$8.6 million, which would amount to a 74% increase compared to the previous quarter. In light of the company’s aggressive expansion strategy into New Jersey and its remarkable success in Pennsylvania, Clarus has also increased TerrAscend’s 2020 earnings projections by C$1.7 million to C$45.5 million, raised the target share price to C$9.00 and reiterated their Buy rating.
TerrAscend’s acquisition of Pennsylvania-based Ilera Healthcare back in August 2019 has proven to be one of the company’s most astute decisions. Pennsylvania’s market has generated over $1 billion in sales since coming online in 2018, and Ilera is on track to generate C$210 million in sales by the end of the year.
As one of the five licensed MSOs in Pennsylvania, Ilera now drives nearly half of the company’s earnings and sells wholesale to over 80% of the state’s dispensaries. In addition to its notable market penetration, Ilera products also have a dedicated consumer following. In an independent study last year, nearly 40% of medical patients voted for Ilera products as their favorite product line, beating out visible competitors including GTI and Cresco Labs.
TerrAscend executives are doubling down on the company’s momentum and expanding to New Jersey’s medical market in the coming months. The rapidly growing market could be one of the most lucrative states in the Northeast. New Jersey currently has over 800,000 active patients and has the potential to serve over 20 million consumers in the mid-Atlantic region if the state legalizes adult-use cannabis this November. TerrAscend is slated to open its first retail location in the Garden State by the end of the year and two more outposts in 2021, but it faces considerable competition from fellow MSO Curaleaf, which has already captured a significant portion of the state’s market share. In order to reach its increased 2021 earnings projection of C$159.7 million, TerrAscend must be prudent and find ways to strategically challenge the current market leader in the region.
Fortunately, New Jersey has committed to increasing its number of dispensaries from 11 to 36, which will provide numerous opportunities for TerrAscend to engage with new consumer audiences and regions. Additionally, growing political interest for legalizing adult-use cannabis in both New Jersey and Pennsylvania will also likely serve as forceful tailwinds that will accelerate the company’s growth.
While the company’s long-term financial standing is contingent on numerous external forces that can change in an instant in this current political and social climate, it appears that TerrAscend has the infrastructure in place to flourish in spite of market volatility. Investors and competing MSOs will be closely watching TerrAscend as it aggressively expands into new territories and asserts its position as a market leader.
Follow me on Twitter or LinkedIn. Check out my website or some of my other work here.
Author: Warren Bobrow
U.S. stock futures sharply lower, Palantir IPO, Novavax, and more
U.S. stock futures were trading sharply lower on Wednesday as growing COVID-19 pandemic dashed hopes of a global economic recovery, despite huge gains in the tech sector during the previous session that propelled the Nasdaq composite to an all-time closing high.
By 5:40 a.m. ET, the blue-chip Dow futures were down 270 points, or 1.03% to 25,909. S&P 500 futures 27.12 points, or 0.85% to 3,144.88 while the tech-heavy Nasdaq 100 futures 45.25 points, or 0.43% to 10,553.25.
There are now more than 130,000 COVID-19 deaths in the U.S., according to data compiled by Johns Hopkins University. Infections have risen in many states and regions over the past two weeks, with Florida, Idaho and U.S. Virgin Islands leading the way.
The dramatic rise in new infections has prompted some states, including Florida and California, to reimpose restrictions.
Shares in Novavax (NASDAQ: NVAX) are surging after the biotechnology company received a contract worth $1.6 billion from President Trump’s “Operation Warp Speed” to develop a coronavirus vaccine.
Novavax said on Tuesday morning that the funds cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the U.S., with the aim of distributing 100 million doses in late 2020 and early 2021.
As of this writing, Novavax stock was up $29.56, or 37.21% to $109 a share in Tuesday’s premarket trading session.
Palantir has submitted confidential documents to the U.S. Securities and Exchange Commission (SEC) for an initial public offering, the company confirmed in a press release Monday.
The data analytics company added that the listing is expected to take place after the SEC completes its review process. However, it did not disclose the size of the offering in the press release.
Palantir was founded by billionaire Peter Thiel in 2004 and offers software that allows organizations integrate their data, their operations and their decisions into one platform.
Last month, Reuters had reported that the company was aiming to file confidentially with the SEC to go public, which could be as soon as September, but the timetable is subject to market conditions and change. It is still weighing whether to go public through a direct listing or a traditional IPO.
Author: Joe A
Industry News: Intravenous Immunoglobulin (IVIg) Market share will grow at CAGR of 5.9 % says Marketstudyreport
The ratio of shares and breakdowns are defined using verified primary sources. The Intravenous Immunoglobulin (IVIg) Market forecast report could be a collection of first-hand info, qualitative and quantitative assessment by Intravenous Immunoglobulin (IVIg) industry analysts, and industry participants across business area.
Request a sample Report of Intravenous Immunoglobulin (IVIg) Market at:https://www.marketstudyreport.com/request-a-sample/1511815?utm_source=marketwatch.com&utm_medium=PC
The Intravenous Immunoglobulin (IVIg) market share registered a valuation of 8120 million in 2018 and is projected to surpass 12800 million by 2025. According to estimates from a Market Study Report LLC report, the Intravenous Immunoglobulin (IVIg) is anticipated to depict a 5.9% CAGR during the 2018-2025 period.
Scope of Intravenous Immunoglobulin (IVIg) Market report:The Intravenous Immunoglobulin (IVIg) Market report provides effective guidelines and strategies for industry players to obtain a position at the top in the Intravenous Immunoglobulin (IVIg) Market. Also, this report is highlighting worldwide and leading key players profiles and serves the eventual guide to discovering opportunities in the Intravenous Immunoglobulin (IVIg) Market industry globally. By implementing several top-down and bottom-up approaches on the historical sales & revenue data and the current Intravenous Immunoglobulin (IVIg) market status, the researchers have forecasted the Intravenous Immunoglobulin (IVIg) market growth and size in key regions. Our experts have added large key companies who play an important role in the production, manufacturing, sales, and distribution of the products. The significant applications and prospective business arenas are also added to Intravenous Immunoglobulin (IVIg) Market outlook report. It fosters the client to make strategic moves and establish their businesses.
Intravenous Immunoglobulin (IVIg) Market Breakdown Data by Companies
Intravenous Immunoglobulin (IVIg) Market Breakdown Data by Type
Intravenous Immunoglobulin (IVIg) Market Breakdown Data by Application
Intravenous Immunoglobulin (IVIg) Market outlook:Apart from exploring into the various segments, the report clustered on key Intravenous Immunoglobulin (IVIg) Market trends and sectors that are either driving or averting the growth of the Intravenous Immunoglobulin (IVIg) industry. Growth policies and plans are mentioned likewise as producing processes and cost structures also are analyzed. The Intravenous Immunoglobulin (IVIg) Market industry development trends are studied through both secondary and primary sources. Finally, the feasibility of the latest investment comes is assessed and overall analysis conclusions offered in Intravenous Immunoglobulin (IVIg) market analysis report.
Market Dynamics:Factors in relation to products like the products prototype, manufacturing method, and r&d development stage are well-explained in the global Intravenous Immunoglobulin (IVIg) Market research report with point-to-point structure and with tables and figures. The report covers the major driving factors influencing the revenue scale of the Intravenous Immunoglobulin (IVIg) market and details about the rising demand for the product from the key geological regions. The Intravenous Immunoglobulin (IVIg) market analyst pot light on different approaches to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the global Intravenous Immunoglobulin (IVIg) Market.
Read Full Report at: https://www.marketstudyreport.com/reports/global-intravenous-immunoglobulin-ivig-market-insights-forecast-to-2025
Frequently Asked Questions
Market Study Report LLC
US Toll Free: 1-866-764-2150
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.
Stocks reverse course in afternoon trading: Three experts on what to watch
Stocks trended lower into the close Tuesday as the tech rally lost steam.
Three experts break down what to watch now.
Ryan Detrick, senior market strategist at LPL Financial, says the historical comparisons are promising for the market.
“We just had a 20% gain in the second quarter. Only eight times since World War II do we gain at least 15%. Think about this — the next quarter was higher every single time. Two quarters later, higher every single time. So there is that sign, that signal that all the strength that we’ve seen earlier this year is consistent, and this sounds crazy, is more consistent with the beginning of a new bull market, not the end of a bull market.”
Chris Hyzy, CIO at Bank of America, says tech should continue to lead the market alongside one other sector.
“Most bull market advances, at least the recent ones in the last two or three decades, have included technology throughout as a leadership group. This time around the bookend to technology is health care. And the reason is technology and health care both have the highest free cash flow collectively in the S&P  to the point where almost 50% of all free cash flow is from those two sectors.”
David Kostin, chief U.S. equity strategist at Goldman Sachs, sees a range-bound market ahead.
“The market in our forecast is likely to be range-bound somewhere between 3,200 on the upper end [of the S&P] and 2,750 or 2,800 on the low end, so that’s the expectation in terms of the range or the path as we move forward into the rest of the year … The narrowness of the market is really pretty striking. In terms of leading stocks you talk about every day and certainly investors like to discuss with me and the other members of the team up like 28% year to date, but the typical stock is actually down basically 8% to 10%. And so I think that that narrowness is likely to continue.”
Author: Keris Lahiff